Lowe Brockenbrough & Co. Inc. decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 2.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 11,899 shares of the medical instruments supplier’s stock after selling 330 shares during the period. Lowe Brockenbrough & Co. Inc.’s holdings in Becton, Dickinson and were worth $2,332,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Almanack Investment Partners LLC. bought a new position in Becton, Dickinson and in the 1st quarter worth about $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its holdings in shares of Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 240 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Becton, Dickinson and by 8.1% in the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after acquiring an additional 51 shares in the last quarter. Harfst & Associates Inc. boosted its holdings in shares of Becton, Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 221 shares in the last quarter. Finally, Financial Architects Inc boosted its holdings in shares of Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after acquiring an additional 54 shares in the last quarter. Hedge funds and other institutional investors own 86.01% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE BDX) traded down $1.21 during trading hours on Friday, hitting $220.31. 718,967 shares of the company traded hands, compared to its average volume of 1,359,118. The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48. The stock has a market cap of $50,134.84, a P/E ratio of 23.21, a PEG ratio of 1.73 and a beta of 1.04. Becton, Dickinson and Company has a fifty-two week low of $161.29 and a fifty-two week high of $225.23.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.12 EPS. sell-side analysts predict that Becton, Dickinson and Company will post 10.63 EPS for the current year.

BDX has been the subject of several recent analyst reports. Wells Fargo & Company reiterated a “positive” rating and issued a $235.00 price objective (up from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. BidaskClub cut shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reiterated a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Morgan Stanley increased their price objective on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a $230.00 price objective (up from $210.00) on shares of Becton, Dickinson and in a report on Friday, November 3rd. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $214.79.

COPYRIGHT VIOLATION WARNING: “Becton, Dickinson and Company (BDX) Holdings Reduced by Lowe Brockenbrough & Co. Inc.” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/11/19/becton-dickinson-and-company-bdx-holdings-reduced-by-lowe-brockenbrough-co-inc.html.

In other news, insider Stephen Sichak sold 11,787 shares of the stock in a transaction on Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the transaction, the insider now owns 14,038 shares in the company, valued at approximately $2,814,057.48. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. In the last quarter, insiders sold 47,038 shares of company stock valued at $9,480,225. Insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.